• Je něco špatně v tomto záznamu ?

Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice

J. Krijt, A. Jonásová, R. Neuwirtová, E. Necas,

. 2010 ; 44 (4) : 257-61. [pub] 20100312

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12025883

Transcription of the hepcidin (Hamp) gene is controlled by iron stores and the rate of erythropoiesis. Functional hierarchy between these two stimuli has not yet been completely established. It is also not known whether the erythropoiesis-related downregulation of Hamp expression utilises the bone morphogenetic protein/hemojuvelin (Bmp/Hjv) pathway. Hemojuvelin-mutant (Hjv-/-) mice treated with erythropoietin (EPO) at 50IU/mouse/day for three days displayed marked decrease in Hamp mRNA, demonstrating that hemojuvelin is not an indispensable component in EPO-induced Hamp gene downregulation. Irradiation of Hjv-/- mice prevented the EPO-induced decrease of Hamp mRNA, highlighting the role of erythropoiesis in Hamp gene regulation by EPO. After a single injection of EPO, Hamp mRNA levels were not significantly changed at 6h, but decreased at 10 and 24h. Chronic bleeding decreased hepatic Bmp6 mRNA levels; however, repeated EPO treatment did not change Bmp6 mRNA, suggesting that the erythropoietic regulator(s) act independently of the Bmp/Hjv pathway. Pretreatment of C57BL/6 mice with iron (5mg/mouse) almost completely inhibited the EPO-induced decrease of Hamp mRNA. This result suggests that administration of EPO to patients with transfusional iron overload is probably not associated with the risk of additional absorption of substantial amounts of iron from the diet.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025883
003      
CZ-PrNML
005      
20121206121059.0
007      
ta
008      
120817e20100312xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.bcmd.2010.02.012 $2 doi
035    __
$a (PubMed)20219396
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krijt, Jan $u Institute of Pathophysiology and Center of Experimental Haematology, Charles University in Prague, First Faculty of Medicine, Prague 2, Czech Republic. JKRI@LF1.CUNI.CZ <JKRI@LF1.CUNI.CZ>
245    10
$a Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice / $c J. Krijt, A. Jonásová, R. Neuwirtová, E. Necas,
520    9_
$a Transcription of the hepcidin (Hamp) gene is controlled by iron stores and the rate of erythropoiesis. Functional hierarchy between these two stimuli has not yet been completely established. It is also not known whether the erythropoiesis-related downregulation of Hamp expression utilises the bone morphogenetic protein/hemojuvelin (Bmp/Hjv) pathway. Hemojuvelin-mutant (Hjv-/-) mice treated with erythropoietin (EPO) at 50IU/mouse/day for three days displayed marked decrease in Hamp mRNA, demonstrating that hemojuvelin is not an indispensable component in EPO-induced Hamp gene downregulation. Irradiation of Hjv-/- mice prevented the EPO-induced decrease of Hamp mRNA, highlighting the role of erythropoiesis in Hamp gene regulation by EPO. After a single injection of EPO, Hamp mRNA levels were not significantly changed at 6h, but decreased at 10 and 24h. Chronic bleeding decreased hepatic Bmp6 mRNA levels; however, repeated EPO treatment did not change Bmp6 mRNA, suggesting that the erythropoietic regulator(s) act independently of the Bmp/Hjv pathway. Pretreatment of C57BL/6 mice with iron (5mg/mouse) almost completely inhibited the EPO-induced decrease of Hamp mRNA. This result suggests that administration of EPO to patients with transfusional iron overload is probably not associated with the risk of additional absorption of substantial amounts of iron from the diet.
650    _2
$a zvířata $7 D000818
650    _2
$a kationické antimikrobiální peptidy $x biosyntéza $x genetika $7 D023181
650    _2
$a kostní morfogenetický protein 6 $x biosyntéza $x genetika $7 D055418
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a erytropoéza $x účinky léků $x genetika $7 D004920
650    _2
$a erythropoetin $x farmakologie $7 D004921
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a železité sloučeniny $x farmakologie $x toxicita $7 D005290
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a přetížení železem $x chemicky indukované $x metabolismus $7 D019190
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové proteiny $x nedostatek $x genetika $x fyziologie $7 D008565
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a polysacharidy $x farmakologie $x toxicita $7 D011134
650    _2
$a messenger RNA $x biosyntéza $7 D012333
650    _2
$a rekombinantní proteiny $7 D011994
650    _2
$a genetická transkripce $x účinky léků $7 D014158
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jonásová, Anna
700    1_
$a Neuwirtová, Radana
700    1_
$a Necas, Emanuel
773    0_
$w MED00005053 $t Blood cells, molecules & diseases $x 1096-0961 $g Roč. 44, č. 4 (20100312), s. 257-61
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20219396 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121206121132 $b ABA008
999    __
$a ok $b bmc $g 947925 $s 783229
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 44 $c 4 $d 257-61 $e 20100312 $i 1096-0961 $m Blood cells, molecules, & diseases $n Blood Cells Mol Dis $x MED00005053
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace